Related Experiment Videos
Ukrain monotherapy in malignant melanoma (case report)
F Hamler1, W Hiesmayr, O Korsh
1Ukrainian Anti-Cancer Institute, Vienna, Austria.
Drugs Under Experimental and Clinical Research
|January 1, 1996
Summary
Ukrain monotherapy effectively treated a patient with stage III malignant melanoma. Melanin excretion ceased after treatment, and the patient remained disease-free for 12 years, indicating a potential long-term remission.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Malignant melanoma is a serious form of skin cancer.
- Metastatic melanoma (stage III) presents a significant treatment challenge.
- Ukrain is a botanical drug derived from the celandine plant (Chelidonium majus).
Observation:
- A patient with stage III malignant melanoma exhibited urinary melanin excretion.
- Melanin was detectable in urine before and during the initial Ukrain treatment course.
Findings:
- Ukrain monotherapy led to the cessation of urinary melanin excretion after the third treatment course.
- The patient achieved and maintained a 12-year disease-free status following Ukrain treatment.
Implications:
- Ukrain may be an effective therapeutic agent for advanced malignant melanoma.
- The resolution of melaninuria suggests a positive response to Ukrain therapy.
- This case highlights the potential for long-term remission in metastatic melanoma patients treated with Ukrain.